#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Comparison of cardiovascular studies with GLP-1 receptor agonists and their implication for clinical practice


Authors: Zbynek Schroner
Authors‘ workplace: SchronerMED s. r. o., Košice
Published in: Diab Obez 2020; 20(39): 51-55
Category: Clinical studies

Overview

Väčšina diabetikov 2. typu je v pásme vysokého alebo veľmi vysokého kardiovaskulárneho (KV) rizika, aj keď ešte nemajú manifestné KV-ochorenie. V súčasnosti ešte prebiehajú, ale väčšinou už boli ukončené veľké klinické dlhodobé randomizované štúdie zamerané na vplyv agonistov GLP1 receptorových agonistov (GLP1 RA) na KV-morbiditu a mortalitu. Liečba GLP1 RA vykazuje viaceré multiorgánové benefity. V rámci individualizovaného prístupu liečba GLP1 RA by mala byť preferovaná už vo včasných štádiach diabetes mellitus 2. typu, so subklinickými prejavmi aterosklerózy, zatiaľ bez manifestného KV-ochorenia.

Keywords:

cardiovascular studies – GLP-1 receptors agonists – implications of studies – type 2 diabetes mellitus


Sources
  1. Haluzík M, Schroner Z. Liečba založená na účinku inkretínov a kardiovaskulárne riziko. In: Antidiabetiká a kardiovaskuslárne riziko. SchronerMed: Košice 2017. ISBN 978–80–8129–073–2 
  2. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373(23): 2247–2257. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1509225>.
  3. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide a cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.
  4. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.
  5. Hernandez AF, Green JB, Janmohamed Set.al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 39(10157): 1519–1529. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32261-X>.
  6. Holman RR, Bethel MA, Mentz RJ et al. [EXSCEL Study Group]. Effect of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228–1239. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1612917>.
  7. Gerstein HC, Colhoun HM, Dagenais GR etal. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double -blind,randomised placebo-controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.
  8. Davies MJ, D Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4729–5>. Erratum in Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). [Diabetologia. 2019].
  9. Davies MJ, D Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0033>.
  10. Buse JB, Wexler D, Tsapas A et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2020; 43(2): 487–493. Dostupné z DOI: <http://dx.doi.org/10.2337/dci19–0066>.
  11. Cosentino F, Grant PJ, Aboyans V et al. [ESC Scientific Document Group]. 2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular diseases developed in collaboration with EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <https://doi: 10.1093/eurheartj/ehz486>.
  12. Schroner Z, Uličiansky V. Miesto agonistov GLP-1 receptorov a ich fixná kombinácia s inzulínom v liečbe diabetes mellitus 2. typu. Vnitr Lek 2019; 65(4): 284–288.
Labels
Diabetology Obesitology

Article was published in

Diabetes and obesity

Issue 39

2020 Issue 39

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#